UUID: 21CF3259- ZESC- 48A6- BGBC- 094001C4D387d
TCGA- LP- ASUZ- 01A- PR

III IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII IIIIIIIIIIIIIIIIIIII IIII II III
IIIIIIIIIIIIIIIIIIIIIIIIIIII IIIIIIIIIIIIII IIIIII II
i””Ililllllllll||IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
Clinical Case Report
(For Collection of Cancerous Tissue) / co ~ 4: 3,
COCF WWW Mom/7nd ﬁnk.
9394 3

PM ~ Wow, NOS fiW/B

5-150 Wx,ms cal?
[Informed Consentl J @1410

 

 

I personally informed this patient that a specimen(s) would be collected to be used for research
puiposes. I reviewed the . RESEARCH SUBJECT INFORMATION AND CONSENT
FORM with the patient and answered any questions the patient had. The patient then signed the
consent form as a free and voluntary act. A copy of this informed consent document will be retained at
our institution.

\

 

 

Name of Phyggaan or Swuj Coordinator Signature Dalte

 

[Clinical Information!

 

GENERAL INFORMATION

1:] Single 421 Married

Gunner CI Divorced D Widow Blood Pressure Heart Rate
[3 Male Female 4'

 

 

HISTORY OF PRESENT ILLNESS
Chief Complaints: - I? “W ‘ ‘3me CW

‘ 5/10 IWVWVUE- VMFIMQE Hmi 1%.

 

 

 

Symptoms: RegimmA/Q— Mad [’99 41m mmf ”Piaf/Lit)“ 063/.
Clinical Findings: w 437 Wee/I05 jg gaminfmw aw
ILL? v21 M158 mega evoke umr MAJ}

w Whig ELMi {V} f6“. ‘étUWLL LN”:

Performance Scale (Karnofsky Score):
D £00 Asymptomatic 80.90 Symptomatic but Fully Ambuiatory a 60—70 Symptomatic, in bed less than 50% of day
:3 40-50 Symptomatic, in bed more than 50% of day, but not bed ridden [3 20'30 Bed Ridden

 

 

 

 

CURRENT MEDICATIONS
Dose Route

 

PAST MEDICAL HISTORY
Disorder

Treatment Status

 

 

 

 

 

 

 

OBIGYN HISTORY
Menopausai Status Date of First Menses # of Pregnancies
E1 Frevmcnopausal D
D Peri-Menopausal Date of Laét Menses # of Live Births
a Postmenopausal ' - C)

 

 

 

ﬁrth Control: [3 Condom C] Oral Contiéacept’ive' U IUD
C) Other: Mi image]

:3 Hormone Replacement

Therapy: “Q

 

 

 

 

SOCIAL HISTORY
Hazards:
H

Current

D YES NO

' Alcohol

Current Status TYPE

III YES NO

Current
E] YES MO

FAMILY MEDICAL HISTORY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LAB DATA

Test Resuit I Date i 1 Test Result Date

HIV dNegative Ci Positive: CEA :3 Negative £3 Positive: LU
Hep B QNegative [3 Positive: CA 15~3 (13 Negative {3 Positive: We
Hep C [:1 Negative D Positive: ' ‘ CA 199 O Negative D Positive: um

AFP Cl Negative E1 Positive: I PSA D Negative [3 Positive: LL“

. g .
Other‘ C3 Negative {:1 Positive: Other. C3 Negative {3 Positive: M71)
1
B/T Cell Markers:

 

 

 

DIAGNOSTIC STUDIES

Results
Ultrasound

X-Ra
CT

MRI
Bi

CLINICAL DIAGNOSIS

K

M -
Location of Involved L Nodes of Distant Metastasis
Lo
Date of
T N M Stage:

 

 

«an.

{Treatment Information! "‘ ‘1: E)

SURGICAL TREATMENT
Date of Procedure

WVW,

Tumor
Location
L “ a. 1

Tumor

Nodes
Lo‘cation of L Nodes
Paipabie, Non-Dissected Lymph Nodes

Dissected Lymph Modes 1 are."

Distant
Detaiied

T N

NEOADJUVENT THERAPY
reatment Route

 

Fathology Form

 

ESpeclmen Information]

 

 

 

 

 

 

 

 

 

 

 

 

 

Collected by: _ Date: Time;
Preserved by: __ Date: _Timc:
L
SPECIMEN TYPE (# of samples provided)
Frozen Paraffin Block Blood/SerumIPlasma Slide
Diseased Normal Diseased Normal Diseased Normal Diseased Normal
M20 Cl (A4) 4... [if
Time to LNZ Time to Formalin Time to LN2
(f (r min 2 (”1 min A § min

 

 

 

 

\Z

Location

I

 

PATHOLOGICAL DESCRIPTION

Tumor

Size Distance to NAT

cm

Extension of Tumor
x cm 13

Nodes
#

X

Distant Metastasis

 

 

Microscopic Description!

 

 

 

 

 

 

 

 

 

 

 

Pattern
Cell Distribution Structural Pattern
Diffuse
Mosaic Storiform
Necrosis
L Inﬁltration
Vascular Invasion
Clusterlzed
Alveolar Formation
Indian File
Cellular Differentiation
+ ~ Adenomatous + - Sarcomatous + - L
Cell cell ‘L Round
Cell Cell Stratiﬁcation Fibroblast Small Cell
Karatin Osteoblast RS Like
4. Inﬂam. Cell
Pearl Gland formation Cell
Cellular Differentiation: Well Moderate Poor
Nuclear
Nuclear
Anise
Nucleoler Prominent
Giant Cell
Nuclear Grade:
IHC Data
ER 0 Positive
a Positive
Her- neu [:1 Positive
B'Celi Marker a Positive
T-Celi Marker a Positive
Other: :3 Positive
Other: :2 Positive
EFinal Pathology Repor'd
i
Histological Diagnosis: #3 [f (2 m n (“a/rm Ham/xi
Grade: 77“
C‘m‘ments’ Car/(11% WM” ‘ﬁyilwcﬁéfélch iioicow Ce?) utommm cam/{353%.1
”3.735 We all P)" m 34W w
' U 8%.
Principal Investigator Pathologist ﬂ ‘uate

 

Consolidated Pathology Diagnosis

Mosaic

Necrosis

L

V Invasion
Clusterized
Alveolar Formation

+ - Adenomatous
Glandular cell
Cell

Vacuole
Pearl Gland
Cellular Differentiation:

Nuclear
Anise Nucleosls

Prominent
Giant

Storiform
Fibrosis

+ - L
Round Cell Cell
Small Cell

Inﬂam. Cell
Plasma Cell

:1 Moderate

0

Nuclear Grade:

 

 

[Final Pathology Reporll

Histological Diagnosis:

wamwxam a

Grade: 3

 

Comments:

 

 

D17? 7516/57 D2, 9:7 Pam?

/’

‘ “‘Lkﬂlﬁﬁt

been is

”T35 MMC dx MW

WW

Home

  
  
   

i

Criteria 2 l 3
Dirnosis Discre oncy
, Primary Tumor Site Discrepancy

f’ \
olx w “Wm hair/WM 7W3" . , , ‘

 

Bale,

 

 

 

V .
TCGA Pathologic Diagnosis Discrepancy Form 4 00

 

 

 

 

 

 

instructions; The TCGA Pathologic Diagnosis Discrepancy Form should be completed when the pathologic diagnosis
documented on the initial pathology report for a case submitted for TC GA is inconsistent with the diagnosis provided on the
Case Quality Control Form completed for the submitted case.

 

 

 

 

Tissue Source Site (TSS): _ TSS identiﬁer: __ ‘TSS Unique Patient identiﬁer;

 

Completed Date: _

 

Completed By (Interviewer Name on OpenClinica): _f_

 

Diagnosis Information

# Data Element Entry Alternatives Working Instructions
Provide the diagnosis/ histologic subtypets) documented on
the initial pathology report for this case. if the histology for

Pathologlc Diagnosis 4%" r i
1 *WD this case is mixed, provide all listed subtypes.

 

 

Provided on Initial
Pathology Report

 

Provide the histologic features selected on the TCGA Case

Histologlc features Of Quality Control Form completed for this case.

the sample provided ﬁtéan’l’gﬁ‘ MAOQ PC Mama
for TCGA, as reﬂected
on the CQCF.

 

 

Discrepancy between Pathology Report and Case Quality Control Form

3 Provide the reason for W i Provide a reason describing why the diagnosis on the initial
. 6'40 Cd? f6 , .4 0 Va? % pathology report for this case is not consistent with the
the discrepancy » 4‘ diagnosis selected on the TCGA Case Quality Control Form.

between the pathology , i 5‘ :
report and the TCGA 4’46 (,6 V") ”k I MIA 1' 65

Case Quality Control é Z Cd ( Viki“ 7.7 l0 d.

 

 

Form. ‘p‘eﬂ
diet/853' Mime/33¢ 5/0420 ‘ .
234714 913,213 Ma’s a we,
6’? C/ {uh/64 7 '
Name OfTSS Reviewing Provide the name of the pathologist who reviewed this case

4- Pathologist or for TCGA.

Biorepository Director

 

 

 

 

 

 

I acknowledge that the above information provided by my institution Is true and correct and has been quality controlled.

 

TSS Reviewing Pathologist or Biorepository Director Date

I acknowledge that the above information provided by my Institution is true and correct and has been quality controlled. The Attending Pathologist or the
Departmentggolrman lms gen informed or is aware oftlre above discrepancy in diagnoses.

 

Principal investigator Signatnre Date

